Cover Image
市場調查報告書

腎細胞癌 (RCC) :市場預測與分析

Renal cell cancer (RCC) disease forecast and market analysis to 2035

出版商 Datamonitor Healthcare 商品編碼 365186
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
腎細胞癌 (RCC) :市場預測與分析 Renal cell cancer (RCC) disease forecast and market analysis to 2035
出版日期: 2018年02月19日 內容資訊: 英文 300 Pages
簡介

本報告提供腎細胞癌治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:腎細胞癌

  • 摘要整理
  • 市場概要·趨勢
  • 調查手法·市場定義
  • Afinitor (everolimus)
  • AGS-003
  • Atezolizumab
  • Avastin (bevacizumab)
  • Cometriq (cabozantinib)
  • Inlyta (axitinib)
  • Lenvima (lenvatinib)
  • Nexavar (sorafenib)
  • Opdivo (nivolumab)
  • Sutent (sunitinib)
  • Torisel (temsirolimus)
  • Votrient (pazopanib)
  • 主要調查手法

治療:腎細胞癌

  • 摘要整理
  • 主要調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療系統
  • 目前治療選擇
  • 處方趨勢

流行病學:腎細胞癌

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優勢與限制

上市藥:腎細胞癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Afinitor
  • 產品簡介:Avastin
  • 產品簡介:Inlyta
  • 產品簡介:Nexavar
  • 產品簡介:Opdivo
  • 產品簡介:Sutent
  • 產品簡介:Torisel
  • 產品簡介:Votrient

開發平台:腎細胞癌

  • 摘要整理
  • 臨床開發平台概要
  • 最近中止的藥物
  • 標靶產品簡介
  • 臨床實驗設計
  • 腎細胞癌的治療的未來
  • 產品簡介 (後期階段) :AGS-003
  • 產品簡介 (後期階段) :Cometriq
  • 產品簡介 (後期階段) :atezolizumab

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5807

DISEASE OVERVIEW

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms' tumor (nephroblastoma). The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market snapshot:

  • The RCC market will experience moderate growth despite a number of patent expiries of key brands over the forecast period.
  • Sutent continues to be the most widely prescribed therapy in locally advanced and metastatic renal cell cancer.
  • Incident cases of renal cell carcinoma are expected to increase by more than a quarter during 2016-36.
  • Sutent is currently the standard of care for newly diagnosed RCC patients, with Afinitor the standard of care in the second-line setting.
  • Companies are increasingly developing pipeline drugs to use in combination with currently marketed therapies.

TABLE OF CONTENTS

(Full Disease Coverage)

FORECAST: RENAL CELL CANCER (Published on 02 March 2017)

  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW AND TRENDS
  • METHODOLOGY AND MARKET DEFINITION
  • AFINITOR (EVEROLIMUS)
  • AVASTIN (BEVACIZUMAB)
  • AVELUMAB
  • CABOMETYX (CABOZANTINIB)
  • INLYTA (AXITINIB)
  • KEYTRUDA (PEMBROLIZUMAB)
  • LENVIMA (LENVATINIB)
  • NEXAVAR (SORAFENIB)
  • OPDIVO (NIVOLUMAB)
  • SUTENT (SUNITINIB)
  • TECENTRIQ (ATEZOLIZUMAB)
  • TORISEL (TEMSIROLIMUS)
  • VOTRIENT (PAZOPANIB)
  • PRIMARY RESEARCH METHODOLOGY

TREATMENT: RENAL CELL CANCER (Published on 16 February 2018)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: RENAL CELL CARCINOMA (Published on 05 February 2018)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: RENAL CELL CANCER (Published on 02 March 2017)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • APPENDIX
  • PRODUCT PROFILE: AFINITOR
  • PRODUCT PROFILE: AVASTIN
  • PRODUCT PROFILE: CABOMETYX
  • PRODUCT PROFILE: INLYTA
  • PRODUCT PROFILE: LENVIMA
  • PRODUCT PROFILE: NEXAVAR
  • PRODUCT PROFILE: OPDIVO
  • PRODUCT PROFILE: SUTENT
  • PRODUCT PROFILE: TORISEL
  • PRODUCT PROFILE: VOTRIENT

PIPELINE: RENAL CELL CANCER (Published on 02 March 2017)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • COMPARATOR THERAPY
  • CLINICAL TRIAL DESIGN
  • APPENDIX
  • PRODUCT PROFILE (LATE STAGE): KEYTRUDA
  • PRODUCT PROFILE (LATE STAGE): TECENTRIQ
  • PRODUCT PROFILE (LATE STAGE): AVELUMAB

LIST OF FIGURES

  • Figure 1: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 2: PD-1/PD-L1 drug sales in renal cell cancer in the US, Japan, and five major EU markets, 2015-24
  • Figure 3: Renal cell cancer drug sales in the US, by status, 2015-24
  • Figure 4: Renal cell cancer drug sales in Japan, by status, 2015-24
  • Figure 5: Renal cell cancer drug sales in the five major EU markets, by status, 2015-24
  • Figure 6: Patient-based forecast methodology for renal cell cancer
  • Figure 7: Price sources and calculations, by country
  • Figure 8: Afinitor sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 9: Avastin sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 10: Avelumab sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 11: Cabometyx sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 12: Inlyta sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 13: Keytruda sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 14: Lenvima sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 15: Nexavar sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 16: Opdivo sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 17: Sutent sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 18: Tecentriq sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 19: Torisel sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 20: Votrient sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Figure 21: Distribution of renal cell cancer patients across the US, Japan, and five major EU markets, by stage and country
  • Figure 22: Percentage of Stage I-III renal cell cancer patients receiving each type of treatment, by country
  • Figure 23: Percentage of Stage IV renal cell cancer patients receiving each treatment type at first-line, by country
  • Figure 24: Top three regimens used in the first-line treatment of Stage IV renal cell cancer patients, by country
  • Figure 25: Percentage of Stage IV renal cell cancer patients currently receiving each line of therapy, by country
  • Figure 26: Top three regimens used in the second-line treatment of Stage IV renal cell cancer, by country
  • Figure 27: Top three regimens used in the third-line treatment of Stage IV renal cell cancer, by country
  • Figure 28: Percentage of local-relapse renal cell cancer patients receiving each treatment type at first-line, by country
  • Figure 29: Percentage of local-relapse renal cell cancer patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
  • Figure 30: Top three regimens used in the first-line treatment of local-relapse renal cell cancer patients, by country
  • Figure 31: Percentage of distant-relapse renal cell cancer patients receiving each treatment type at first-line, by country
  • Figure 32: Top three regimens used in the first-line treatment of distant-relapse renal cell cancer patients, by country
  • Figure 33: Percentage of distant-relapse renal cell cancer patients currently receiving each line of therapy, by country
  • Figure 34: Top three regimens used in the second-line treatment of distant-relapse renal cell cancer patients, by country
  • Figure 35: Top three regimens used in the third-line treatment of distant-relapse renal cell cancer patients, by country
  • Figure 36: Trends in incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, 2016-36
  • Figure 37: Datamonitor Healthcare's drug assessment summary of key marketed drugs for renal cell cancer
  • Figure 38: Afinitor for renal cell cancer - SWOT analysis
  • Figure 39: Datamonitor Healthcare's drug assessment summary of Afinitor for renal cell cancer
  • Figure 40: Datamonitor Healthcare's drug assessment summary of Afinitor for renal cell cancer
  • Figure 41: Avastin for renal cell cancer - SWOT analysis
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Avastin for renal cell cancer
  • Figure 43: Datamonitor Healthcare's drug assessment summary of Avastin for renal cell cancer
  • Figure 44: Cabometyx for renal cell cancer - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Cabometyx for renal cell cancer
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Cabometyx for renal cell cancer
  • Figure 47: Inlyta for renal cell cancer - SWOT analysis
  • Figure 48: Datamonitor Healthcare's drug assessment summary of Inlyta for renal cell cancer
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Inlyta for renal cell cancer
  • Figure 50: Lenvima for renal cell cancer - SWOT analysis
  • Figure 51: Datamonitor Healthcare's drug assessment summary of Lenvima for renal cell cancer
  • Figure 52: Datamonitor Healthcare's drug assessment summary of Lenvima for renal cell cancer
  • Figure 53: Nexavar for renal cell cancer - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Nexavar for renal cell cancer
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Nexavar for renal cell cancer
  • Figure 56: Opdivo pivotal trial data in renal cell cancer
  • Figure 57: Opdivo for renal cell cancer - SWOT analysis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of Opdivo for renal cell cancer
  • Figure 59: Datamonitor Healthcare's drug assessment summary of Opdivo for renal cell cancer
  • Figure 60: Sutent for renal cell cancer - SWOT analysis
  • Figure 61: Datamonitor Healthcare's drug assessment summary of Sutent for renal cell cancer
  • Figure 62: Datamonitor Healthcare's drug assessment summary of Sutent for renal cell cancer
  • Figure 63: Torisel for renal cell cancer - SWOT analysis
  • Figure 64: Datamonitor Healthcare's drug assessment summary of Torisel for renal cell cancer
  • Figure 65: Datamonitor Healthcare's drug assessment summary of Torisel for renal cell cancer
  • Figure 66: Votrient for renal cell cancer - SWOT analysis
  • Figure 67: Datamonitor Healthcare's drug assessment summary of Votrient for renal cell cancer
  • Figure 68: Datamonitor Healthcare's drug assessment summary of Votrient for renal cell cancer
  • Figure 69: Sutent pivotal Phase III trial data in renal cell cancer
  • Figure 70: Keytruda for renal cell cancer - SWOT analysis
  • Figure 71: Datamonitor Healthcare's drug assessment summary of Keytruda for renal cell cancer
  • Figure 72: Datamonitor Healthcare's drug assessment summary of Keytruda for renal cell cancer
  • Figure 73: Tecentriq for renal cell cancer - SWOT analysis
  • Figure 74: Datamonitor Healthcare's drug assessment summary of Tecentriq for renal cell cancer
  • Figure 75: Datamonitor Healthcare's drug assessment summary of Tecentriq for renal cell cancer
  • Figure 76: Avelumab for renal cell cancer - SWOT analysis
  • Figure 77: Datamonitor Healthcare's drug assessment summary of avelumab for renal cell cancer
  • Figure 78: Datamonitor Healthcare's drug assessment summary of avelumab for renal cell cancer

LIST OF TABLES

  • Table 1: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 2: PD-1/PD-L1 renal cell cancer drug sales in the US, Japan, and five major EU markets, by brand ($m), 2015-24
  • Table 3: Renal cell cancer drug sales in the US, by brand and status ($m), 2015-24
  • Table 4: Renal cell cancer drug sales in Japan, by brand and status ($m), 2015-24
  • Table 5: Renal cell cancer drug sales in the five major EU markets, by brand and status ($m), 2015-24
  • Table 6: Summary of drug classes and molecules in Datamonitor Healthcare's renal cell cancer patient-based forecast
  • Table 7: Exchange rates used for calculating prices
  • Table 8: Patent expiry dates for key marketed brands in renal cell cancer in the US, Japan, and five major EU markets, 2015-24
  • Table 9: Datamonitor Healthcare's estimated launch dates of key late-stage pipeline products and marketed brands in renal cell cancer, 2015-24
  • Table 10: Afinitor sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 11: Afinitor patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 12: Avastin sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 13: Avastin patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 14: Avelumab sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 15: Avelumab patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 16: Cabometyx sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 17: Cabometyx patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 18: Inlyta sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 19: Inlyta patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 20: Keytruda sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 21: Keytruda patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 22: Lenvima sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 23: Lenvima patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 24: Nexavar sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 25: Nexavar patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 26: Opdivo sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 27: Opdivo patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 28: Sutent sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 29: Sutent patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 30: Tecentriq sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 31: Tecentriq patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 32: Torisel sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 33: Torisel patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 34: Votrient sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
  • Table 35: Votrient patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
  • Table 36: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2015
  • Table 37: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2017
  • Table 38: Renal cell cancer five-year survival rates, by stage at diagnosis
  • Table 39: TNM classification, by stage at diagnosis
  • Table 40: Leading treatments for renal cell cancer across the US, Japan, and five major EU markets
  • Table 41: Cancer registry databases used as a source of renal cell carcinoma incidence data, by country
  • Table 42: Forecasting methodology for renal cell incidence, by country, age group, and gender
  • Table 43: Sources of survival data used to estimate renal cell carcinoma prevalence, by country
  • Table 44: Incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 45: Key marketed drugs for renal cell cancer
  • Table 46: Afinitor drug profile
  • Table 47: Afinitor pivotal Phase III trial data in renal cell cancer
  • Table 48: Avastin drug profile
  • Table 49: Avastin pivotal Phase III trial data in renal cell cancer
  • Table 50: Cabometyx drug profile
  • Table 51: Cabometyx pivotal Phase III trial data in renal cell cancer
  • Table 52: Inlyta drug profile
  • Table 53: Inlyta pivotal Phase III trial data in renal cell cancer
  • Table 54: Lenvima drug profile
  • Table 55: Lenvima pivotal Phase II trial data in renal cell cancer
  • Table 56: Lenvima ongoing Phase III clinical trial in renal cell cancer
  • Table 57: Nexavar drug profile
  • Table 58: Nexavar pivotal Phase III trial data in renal cell cancer
  • Table 59: Opdivo drug profile
  • Table 60: Opdivo ongoing Phase III clinical trial in renal cell cancer
  • Table 61: Sutent drug profile
  • Table 62: Overview of pivotal Phase III trial data for Sutent in renal cell cancer
  • Table 63: Sutent ongoing Phase III clinical trial in renal cell cancer
  • Table 64: Torisel drug profile
  • Table 65: Torisel pivotal Phase III trial data in renal cell cancer
  • Table 66: Votrient drug profile
  • Table 67: Votrient pivotal Phase III trial data in renal cell cancer
  • Table 68: Votrient Phase III trial data in renal cell cancer
  • Table 69: Votrient ongoing late-phase clinical trial in renal cell cancer
  • Table 70: Phase III pipeline products in development for renal cell cancer
  • Table 71: PD-1/PD-L1 Phase III combination regimens in development for advanced renal cell cancer
  • Table 72: Late-stage compounds that were recently discontinued for renal cell cancer
  • Table 73: Sutent drug profile
  • Table 74: Typical Phase III clinical trial design in renal cell cancer
  • Table 75: Clinical endpoints that led to the approval of current treatments for renal cell cancer
  • Table 76: Summary of therapeutic classes in renal cell cancer by ATC code
  • Table 77: Keytruda drug profile
  • Table 78: Keytruda Phase III trial in renal cell cancer
  • Table 79: Tecentriq drug profile
  • Table 80: Tecentriq Phase III trial in renal cell cancer
  • Table 81: Avelumab drug profile
  • Table 82: Avelumab Phase III trial in renal cell cancer
Back to Top